Recent 8-K filings for MBOT
Highest-materiality recent filing
Microbot Medical receives FDA 510(k) clearance for LIBERTY Endovascular Robotic System
- FDA 510(k) clearance for LIBERTY System, first single-use remotely operated robotic system for peripheral endovascular procedures.
- Pivotal study showed 100% robotic navigation success and zero device-related adverse events; 92% relative reduction in physician radiation exposure.
-
Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.
Israeli Ministry of Health's AMAR Division grants marketing clearance for LIBERTY Endovascular Robotic System in Israel.
-
Microbot Medical records first revenue from LIBERTY; Q2 revenue already exceeds Q1
Recorded revenue from limited market release of LIBERTY System in Q1 2026; transitioned to full market release in Q2.
-
LIBERTY Endovascular Robotic System won accounts in key U.S. territories, including two ACCESS-PVI trial sites.
-
CEO Harel Gadot will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 10:15 a.m. ET.
-
LIBERTY adopted by multiple healthcare systems including Emory Healthcare and Tampa General Hospital during limited market release.
-
Emory performs first robotic PAE and Y-90 mapping using Microbot's LIBERTY System
World's first robotic prostate artery embolization (PAE) for BPH performed with LIBERTY at Emory.
-
Microbot Medical's LIBERTY pivotal study published in JVIR; full market launch in April 2026
ACCESS-PVI study published in JVIR, a top radiology journal, after independent peer review.
-
Tampa General Hospital first in Florida to adopt Microbot's LIBERTY robotic system
Tampa General Hospital (TGH) becomes first Florida health system to adopt LIBERTY Endovascular Robotic System after FDA 510(k) clearance.
-
Emory University Hospital in Atlanta is first hospital globally to adopt Microbot's LIBERTY Endovascular Robotic System for patient care.
-
Microbot Medical launches limited U.S. commercial release of LIBERTY robotic system
LIBERTY Endovascular Robotic System now commercially available in U.S. on a limited basis after FDA 510(k) clearance in September 2025.
-
Microbot Medical to debut LIBERTY System at CIO meeting; hires commercial team
First commercial exhibition of LIBERTY Endovascular Robotic System at CIO symposium in Miami, Oct 17-19, 2025.
-
Microbot partners with US logistics provider; LIBERTY launch on track for Q4 2025
Partnered with an experienced medtech 3PL company for inventory management and order fulfillment.
-
Microbot Medical completes final PIO exercise closing, raising $29.2M initial gross proceeds
Three closings: $25.2M (first), $1.2M (second), $2.8M (third) – total $29.2M gross proceeds before fees.
-
Japanese Patent Office granted first Japan patent covering core LIBERTY System technology for compact robotic surgical tool.
-
Microbot Medical raises $25.2M in first close of PIO exercise; potential total $92.2M
First closing on Sep 16 generated ~$25.2M gross; second closing expected by Oct 15 for ~$4M.
-
Microbot Medical receives FDA 510(k) clearance for LIBERTY Endovascular Robotic System
FDA 510(k) clearance for LIBERTY System, first single-use remotely operated robotic system for peripheral endovascular procedures.
-
Microbot Medical issues 4.06M shares on option exercises, raises ~$8.6M
Issued 300,000 Series H option shares at $2.10 and 3,755,870 Series I option shares at $2.13.
-
Microbot Medical granted USPTO patent expanding LIBERTY system TAM to 6M+ US procedures
Patent covers modular robotic system with interchangeable tool-receiver units attachable to base.
-
Microbot Medical raises ~$7.6M from option exercises, receives NIS 2.15M IIA grant
Issued 4,344,286 shares at $1.75 upon exercise of Series G options, gross proceeds $7.6M.
-
Microbot Medical issues 2.4M shares on warrant exercises, raising $4.2M
Issued 2,395,715 shares of common stock upon exercise of Series G preferred investment options since July 17, 2025.
-
Microbot Medical appoints Christina Bailey as VP of Sales ahead of LIBERTY launch
Christina Bailey named VP of Sales; reports to CEO Harel Gadot.
-
Microbot Medical raises ~$3.0M via exercise of Series F and G options
Issued 1,808,336 shares upon exercise of 1,025,000 Series G and 783,336 Series F options since June 18, 2025.
-
Participates in Society of Robotic Surgery annual meeting July 16-20 in Strasbourg, France.
-
Microbot Medical expects FDA 510(k) decision for LIBERTY System in Q3 2025; hires sales ops head
Added Michael Lytle as head of Sales Operations & Analytics to strengthen pre-launch infrastructure.
-
Issued 1,533,336 common shares upon exercise of Series F and Series E preferred investment options at $1.50/share, generating ~$2.3M gross proceeds.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.57 · Most common event other_material